Clinical Trial Update: Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating serplulimab combined with an anti-VEGF antibody in advanced lung adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Serplulimab (serplulimab)
• anti-VEGF antibody

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN